Back to Search
JAMES VREDENBURGH, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1609950575Individual
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
39132(NC)
Research & Publications (20)
Experience with irinotecan for the treatment of malignant glioma.
PMID 18784279·Neuro Oncol·2009
6-review
Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients.
PMID 19415455·J Neurooncol·2009
3-trial
Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
PMID 19533023·J Neurooncol·2009
3-trial
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
PMID 17947719·J Clin Oncol·2007
3-trial
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
PMID 17317837·Clin Cancer Res·2007
3-trial
Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone.
PMID 16443517·Biol Blood Marrow Transplant·2006
4-observational
A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy.
PMID 16633363·Bone Marrow Transplant·2006
3-trial
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
PMID 19562254·J Neurooncol·2010
3-trial
Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing.
PMID 19212703·J Neurooncol·2009
8-other
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
PMID 19248046·Cancer·2009
3-trial
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
PMID 19289491·Neuro Oncol·2009
3-trial
Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme.
PMID 19388113·J Magn Reson Imaging·2009
8-other
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
PMID 19402172·Cancer·2009
3-trial
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
PMID 19204199·J Clin Oncol·2009
3-trial
Computerized assessment of vessel morphological changes during treatment of glioblastoma multiforme: report of a case imaged serially by MRA over four years.
PMID 19103295·Neuroimage·2009
5-case
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
PMID 19514083·Cancer·2009
8-other
Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
PMID 19188181·Clin Cancer Res·2009
3-trial
Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.
PMID 18471045·Expert Rev Anticancer Ther·2008
6-review
Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma.
PMID 18755919·Neuro Oncol·2008
8-other
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
PMID 18981004·Clin Cancer Res·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2100 ERWIN RD
DURHAM, NC 27710 - Phone
- (919) 620-4467
Quick Facts
- NPI
- 1609950575
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile